Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451
(WorldNews Belgium)

Press release 23 February 2017, 22.00 CET Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451 Mechelen, Belgium; 23 February 2017 - Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first healthy volunteer with a combination of novel corrector GLPG2222 and novel potentiator GLPG2451 for cystic fibrosis in a Phase 1 study. After completion of the dosing of GLPG2451 as a monotherapy, in the new cohorts the safety, tolerability and PK of 14 days co-administration of GLPG2451 and GLPG2222 is being evaluated. The randomized, double-blind, placebo controlled, single center study is being conducted in at least 40 healthy volunteers in Belgium. In order to...